Tissue plasminogen activator-based nanothrombolysis for ischemic stroke

Shan Liu, Xiaozhou Feng, Rong Jin, Guohong Li

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

Introduction: Thrombolysis with intravenous tissue plasminogen activator (tPA) is the only FDA approved treatment for patients with acute ischemic stroke, but its use is limited by narrow therapeutic window, selective efficacy, and hemorrhagic complication. In the past two decades, extensive efforts have been undertaken to extend its therapeutic time window and explore alternative thrombolytic agents, but both show little progress. Nanotechnology has emerged as a promising strategy to improve the efficacy and safety of tPA. Areas covered: We reviewed the biology, thrombolytic mechanism, and pleiotropic functions of tPA in the brain and discussed current applications of various nanocarriers intended for the delivery of tPA for treatment of ischemic stroke. Current challenges and potential further directions of t-PA-based nanothrombolysis in stroke therapy are also discussed. Expert opinion: Using nanocarriers to deliver tPA offers many advantages to enhance the efficacy and safety of tPA therapy. Further research is needed to characterize the physicochemical characteristics and in vivo behavior of tPA-loaded nanocarriers. Combination of tPA based nanothrombolysis and neuroprotection represents a promising treatment strategy for acute ischemic stroke. Theranostic nanocarriers co-delivered with tPA and imaging agents are also promising for future stroke management.

Original languageEnglish (US)
Pages (from-to)173-184
Number of pages12
JournalExpert Opinion on Drug Delivery
Volume15
Issue number2
DOIs
StatePublished - Feb 1 2018

Fingerprint

Tissue Plasminogen Activator
Stroke
Therapeutics
Safety
Nanotechnology
Fibrinolytic Agents
Expert Testimony
Brain
Research

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science

Cite this

@article{0a78c6bbc83b45e7a16327c7c72baa11,
title = "Tissue plasminogen activator-based nanothrombolysis for ischemic stroke",
abstract = "Introduction: Thrombolysis with intravenous tissue plasminogen activator (tPA) is the only FDA approved treatment for patients with acute ischemic stroke, but its use is limited by narrow therapeutic window, selective efficacy, and hemorrhagic complication. In the past two decades, extensive efforts have been undertaken to extend its therapeutic time window and explore alternative thrombolytic agents, but both show little progress. Nanotechnology has emerged as a promising strategy to improve the efficacy and safety of tPA. Areas covered: We reviewed the biology, thrombolytic mechanism, and pleiotropic functions of tPA in the brain and discussed current applications of various nanocarriers intended for the delivery of tPA for treatment of ischemic stroke. Current challenges and potential further directions of t-PA-based nanothrombolysis in stroke therapy are also discussed. Expert opinion: Using nanocarriers to deliver tPA offers many advantages to enhance the efficacy and safety of tPA therapy. Further research is needed to characterize the physicochemical characteristics and in vivo behavior of tPA-loaded nanocarriers. Combination of tPA based nanothrombolysis and neuroprotection represents a promising treatment strategy for acute ischemic stroke. Theranostic nanocarriers co-delivered with tPA and imaging agents are also promising for future stroke management.",
author = "Shan Liu and Xiaozhou Feng and Rong Jin and Guohong Li",
year = "2018",
month = "2",
day = "1",
doi = "10.1080/17425247.2018.1384464",
language = "English (US)",
volume = "15",
pages = "173--184",
journal = "Expert Opinion on Drug Delivery",
issn = "1742-5247",
publisher = "Informa Healthcare",
number = "2",

}

Tissue plasminogen activator-based nanothrombolysis for ischemic stroke. / Liu, Shan; Feng, Xiaozhou; Jin, Rong; Li, Guohong.

In: Expert Opinion on Drug Delivery, Vol. 15, No. 2, 01.02.2018, p. 173-184.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Tissue plasminogen activator-based nanothrombolysis for ischemic stroke

AU - Liu, Shan

AU - Feng, Xiaozhou

AU - Jin, Rong

AU - Li, Guohong

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Introduction: Thrombolysis with intravenous tissue plasminogen activator (tPA) is the only FDA approved treatment for patients with acute ischemic stroke, but its use is limited by narrow therapeutic window, selective efficacy, and hemorrhagic complication. In the past two decades, extensive efforts have been undertaken to extend its therapeutic time window and explore alternative thrombolytic agents, but both show little progress. Nanotechnology has emerged as a promising strategy to improve the efficacy and safety of tPA. Areas covered: We reviewed the biology, thrombolytic mechanism, and pleiotropic functions of tPA in the brain and discussed current applications of various nanocarriers intended for the delivery of tPA for treatment of ischemic stroke. Current challenges and potential further directions of t-PA-based nanothrombolysis in stroke therapy are also discussed. Expert opinion: Using nanocarriers to deliver tPA offers many advantages to enhance the efficacy and safety of tPA therapy. Further research is needed to characterize the physicochemical characteristics and in vivo behavior of tPA-loaded nanocarriers. Combination of tPA based nanothrombolysis and neuroprotection represents a promising treatment strategy for acute ischemic stroke. Theranostic nanocarriers co-delivered with tPA and imaging agents are also promising for future stroke management.

AB - Introduction: Thrombolysis with intravenous tissue plasminogen activator (tPA) is the only FDA approved treatment for patients with acute ischemic stroke, but its use is limited by narrow therapeutic window, selective efficacy, and hemorrhagic complication. In the past two decades, extensive efforts have been undertaken to extend its therapeutic time window and explore alternative thrombolytic agents, but both show little progress. Nanotechnology has emerged as a promising strategy to improve the efficacy and safety of tPA. Areas covered: We reviewed the biology, thrombolytic mechanism, and pleiotropic functions of tPA in the brain and discussed current applications of various nanocarriers intended for the delivery of tPA for treatment of ischemic stroke. Current challenges and potential further directions of t-PA-based nanothrombolysis in stroke therapy are also discussed. Expert opinion: Using nanocarriers to deliver tPA offers many advantages to enhance the efficacy and safety of tPA therapy. Further research is needed to characterize the physicochemical characteristics and in vivo behavior of tPA-loaded nanocarriers. Combination of tPA based nanothrombolysis and neuroprotection represents a promising treatment strategy for acute ischemic stroke. Theranostic nanocarriers co-delivered with tPA and imaging agents are also promising for future stroke management.

UR - http://www.scopus.com/inward/record.url?scp=85042562379&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042562379&partnerID=8YFLogxK

U2 - 10.1080/17425247.2018.1384464

DO - 10.1080/17425247.2018.1384464

M3 - Review article

C2 - 28944694

AN - SCOPUS:85042562379

VL - 15

SP - 173

EP - 184

JO - Expert Opinion on Drug Delivery

JF - Expert Opinion on Drug Delivery

SN - 1742-5247

IS - 2

ER -